Key facts
- Eisai will invest $64 million in its UK manufacturing facility.
- The investment is for packaging injectable drugs.
- Eisai is a Japanese pharmaceutical company.
- The company focuses on neurology, oncology, and tropical diseases.
Japanese pharmaceutical firm Eisai is set to invest $64 million to enhance its UK manufacturing plant's capabilities for packaging injectable drugs. The company, headquartered in Japan, focuses its research and development efforts on therapeutic areas including neurology, oncology, and tropical diseases.
Eisai operates 15 drug discovery research and development sites worldwide, with a presence in the UK contributing to its global network. The company is known for its work in neurology, aiming to develop treatments for neurodegenerative diseases, and notably collaborated with Biogen on the anti-amyloid therapy lecanemab for early-stage Alzheimer's disease.
The investment in the UK facility is expected to bolster Eisai's production capacity for its range of treatments.